Center for Continuing Education
About The Cleveland Clinic Center for Continuing Education | Call or Email Us | About The Cleveland Clinic
Live Cleveland Clinic CME Courses |  Regularly Scheduled Series (RSS) Registration | Regulary Scheduled Series (RSS) Schedule (pdf)
Disease Management Project Clinical Decisions Cases |  Hepatitis C Management |  Managing Problem Patients with Anti-TNF Inhibitors |  More
Medicine Today Series |  B Cell Series |  Emerging Therapies in Heart Disease Webcast Series |  More
Disease Management Project |  CCJM 1-Minute Consult |  Pharmacotherapy Update Newsletter |  Algorithms for the MICU |  More
Cleveland Clinic Foundation CME Home Contact Us Live CME Courses Online CME Topics Webcasts Online Medical Publications my CME Search Sitemap e-mail Newsletter
Rheumatoid Arthritis eJournal Club
   

Efficacy and Safety of Abatacept or Infliximab vs Placebo in ATTEST:
A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled
Study in Patients With Rheumatoid Arthritis and an Inadequate
Response to Methotrexate

Publication: Schiff M, et al. Ann Rheum Dis. 2008;67:1096-1103.
 
Release Date: November 21, 2008 Expiration Date: November 21, 2009

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion 45 minutes
Description / Overview

The purpose of this activity is to assess the relative efficacy and safety of abatacept and infliximab in a single, double-blind, randomized, placebo-controlled study.
Objectives At the conclusion of this activity, the participant will be able to:
  1. Outline the study design of ATTEST.
  2. Compare and contrast the effectiveness of abatacept and infliximab on disease activity, physical function, and quality of life.
  3. Describe the adverse events reported in the abatacept and infliximab groups.
Target Audience This activity is directed to physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in RA.
Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty Michael H. Schiff, MD
Faculty Disclosure In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
Leonard Calabrese, DO  
  Consulting: Abbott Laboratories; Elan; Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.
 
Michael H. Schiff, MD  
  Consulting: Bristol-Myers Squibb Company
 
  Board Membership: Bristol-Myers Squibb Company

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:

Roche Laboratories, Inc.

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME.

Contact Information | Privacy Policy | Disclaimer

Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.